(Q39186157)

9 September 2017

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. (English)

1 reference

9 September 2017

7

1 reference

9 September 2017

H Rizos

11

0 references

author name string

T M Becker

1

1 reference

9 September 2017

S C Boyd

2

1 reference

9 September 2017

B Mijatov

3

1 reference

9 September 2017

K Gowrishankar

4

1 reference

9 September 2017

S Snoyman

5

1 reference

9 September 2017

G M Pupo

6

1 reference

9 September 2017

G J Mann

8

1 reference

9 September 2017

R F Kefford

9

1 reference

9 September 2017

X D Zhang

10

1 reference

9 September 2017

language of work or name

English

0 references

publication date

4 March 2013

1 reference

9 September 2017

1 reference

9 September 2017

33

1 reference

9 September 2017

1158-1166

1 reference

9 September 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2013.45

9 September 2017

0 references

cites work

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

BRAF as therapeutic target in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

BRAF signaling and targeted therapies in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Mcl-1 is required for melanoma cell resistance to anoikis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Targeting STAT3 affects melanoma on multiple fronts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Stats: transcriptional control and biological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

BRAFE600-associated senescence-like cell cycle arrest of human naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

c-Src activates both STAT1 and STAT3 in PDGF-stimulated NIH3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Activation of stat3 in human melanoma promotes brain metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Mcl-1 is a potential therapeutic target in multiple types of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Cutaneous Malignant Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Nuclear expression of the antiapoptotic protein survivin in malignant melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

Activated Stat-3 in Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

A new small-molecule Stat3 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.45

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.45

1 reference

Dimensions Publication ID

9 September 2017

1002813670

0 references

Fatcat ID

release_rxlbt6kvxbac3gvhpsw5l2njj4

0 references

1 reference